EPISODE · May 26, 2023 · 15 MIN
MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall
from MPR Weekly Dose
First oral antiviral approved for COVID-19; First topical treatment approved for epidermolysis bullosa; Xacduro gets green like for bacterial pneumonia; New nasal spray for opioid overdoses; Child cough suppressant recalled.
Embed this episode
Ready to play
MPR Weekly Dose 161 — First Oral Antiviral Approved for COVID-19; First Topical Tx for Epidermolysis Bullosa; Xacduro and Opvee Approved; Cough Suppressant Recall
0:00
15:35
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of MPR Weekly Dose?
This episode is 15 minutes long.
When was this MPR Weekly Dose episode published?
This episode was published on May 26, 2023.
Can I download this MPR Weekly Dose episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!